Comparative effects of CPAP and Mandibular Advancement Device Treatment on Cardiac Structure and Function in OSA: A Cardiovascular Magnetic Resonance Randomised Controlled Study

Short title: CRESCENT CMR Substudy

Nithin R. Iyer MBBS[1,2],* Yi-hui Ou BSc(Pharm)[3],* Jennifer A. Bryant PhD[2], Thu-Thao Le PhD[2,4], Juliana Tereza Colpani DDS MS[5], Crystal S. Cheong MBBS[6], Weiqiang Loke BDS[5], Peter A. Cistulli MBBS PhD[7,8], Martin Ugander MD PhD[1,9], Chi-hang Lee MBBS MD[3,10,11] and Calvin W-L. Chin MD PhD[2,4,12]

[1]Kolling Institute, Royal North Shore Hospital, and the University of Sydney, Sydney, Australia

[2]National Heart Research Institute of Singapore, National Heart Centre Singapore, Singapore

[3]Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

[4]Cardiovascular Sciences ACP, Duke NUS Medical School, Singapore

[5]Department of Endodontics, Operative Dentistry and Prosthodontics, Faculty of Dentistry, National University of Singapore, Singapore

[6]Department of Otolaryngology–Head & Neck Surgery, National University Hospital, Singapore, Singapore

[7]Sleep Research Group, Charles Perkins Centre and Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia

[8]Department of Respiratory and Sleep Medicine, Royal North Shore Hospital, St Leonards, New South Wales, Australia

[9]Department of Clinical Physiology, Karolinska University Hospital, and Karolinska Institutet, Stockholm, Sweden

[10]Cardiovascular Research Institute, National University Heart Centre, Singapore, Singapore

[11]Department of Cardiology, National University Heart Centre, Singapore, Singapore

[12]Department of Cardiology, National Heart Centre Singapore, Singapore

*N.R. Iyer and Y-h. Ou contributed equally as first authors

Corresponding Author
A/Prof Calvin Chin
Department of Cardiology
5 Hospital Drive, Singapore 169609

Word Count: 6449 words
3 Figures and 5 Tables (including Supplemental tables)

Non-standard Abbreviations and Acronyms

CMR: Cardiovascular magnetic resonance

CPAP: Continuous positive airway pressure

ECV: Myocardial extracellular volume fraction

LV: left ventricle

MAD: Mandibular advancement device

OSA: Obstructive sleep apnoea

Abstract

Background

Adverse cardiac remodelling, including left ventricular (LV) hypertrophy, LV dysfunction

and diffuse myocardial fibrosis, is observed in obstructive sleep apnoea (OSA). However, the

impact of OSA treatment on cardiac remodelling remains poorly defined. The Cardiosleep

Research Program on Obstructive Sleep Apnoea, Blood Pressure Control and Maladaptive

Myocardial Remodeling—Non-inferiority Trial (CRESCENT) showed that treatment with a

mandibular advancement device (MAD) was non-inferior to continuous positive airway

pressure (CPAP) for reducing 24-hour mean arterial BP in patients with hypertension and

moderate-to-severe OSA, after 6 months of treatment. This cardiovascular magnetic

resonance (CMR) substudy of the CRESCENT trial aimed to evaluate the comparative effects

of MAD and CPAP on myocardial structure and function in patients with OSA.

Methods

85 patients with hypertension, increased cardiovascular risk and newly-diagnosed moderate-

to-severe OSA (Apnoea-Hypopnoea Index [AHI] $\geq$15 events/hour), underwent contrast-

enhanced CMR at baseline and following 12 months of treatment with CPAP (n=49) or MAD

(n=36). LV mass, volumes, function and markers of diffuse myocardial fibrosis, including the

extracellular volume (ECV) fraction and interstitial volume, were measured.

Results

Across the cohort (age: 61[54-66] years, 91% males, BMI: 28[26-31] kg/m^2, and AHI: 41[27-

59] events/hour), a modest reduction in the ECV fraction was observed (25.0±2.0 vs

24.3±2.0%; p<0.001), accompanied by a reduction in the interstitial volume over a 12-month

period of OSA treatment (24.0[21.3-27.7] vs 23.3[20.4-27.4]mL; p=0.044). The reduction in

ECV fraction was similar between the CPAP and MAD groups (p=0.94).

Conclusion

12 months treatment of OSA in patients with hypertension is associated with a reduction in

myocardial ECV fraction, a surrogate marker of diffuse myocardial fibrosis, with

accompanying reduction in myocardial interstitial volume. Both CPAP and MAD were

similarly effective. Further confirmation of these findings in larger cohorts is warranted.

(Cardiosleep Research Program on Obstructive Sleep Apnea, Blood Pressure Control and

Maladaptive Myocardial Remodeling—Non-inferiority Trial [CRESCENT]; NCT04119999).

Introduction

Obstructive sleep apnoea (OSA) is a highly prevalent condition that is thought to affect nearly

1 billion people worldwide [1]. Patients with OSA develop recurrent collapse of the pharyngeal

airway during sleep, resulting in intermittent hypoxaemia, sympathetic activation, and

exaggerated intrathoracic pressure swings [2]. These perturbations are associated with acute

and chronic haemodynamic effects, and particularly alterations in blood pressure [3, 4]. OSA is

associated with several cardiovascular complications, including hypertension, atrial fibrillation,

heart failure, coronary artery disease, stroke, pulmonary hypertension, metabolic syndrome,

diabetes and sudden cardiac death.

Adverse cardiac remodelling is often observed in OSA, including left ventricular (LV)

hypertrophy, left and right ventricular dysfunction, and focal myocardial fibrosis [5-7]. There is

emerging evidence that treatment of OSA with continuous positive airway pressure (CPAP),

the primary treatment for OSA, is associated with improvement in left ventricular function, in

addition to right ventricular systolic function [8-10]. Mandibular advancement devices (MAD)

treat OSA by advancing the mandible and are an effective alternative to CPAP, demonstrating

improvement in OSA symptoms and quality of life [11-13]. Few studies have assessed the

effect of MAD on ventricular structure and function in patients with OSA. One

echocardiographic study showed improvement in LV hypertrophy in patients with OSA treated

with MAD for six months [14]. Additionally, it is not known whether treatment of OSA, with

either MAD or CPAP, can reverse myocardial fibrosis.

Cardiovascular magnetic resonance (CMR) imaging has become the non-invasive reference

standard for interrogating the myocardium due to its ability to accurately assess cardiac

morphology, function, and myocardial tissue characteristics. In particular, late gadolinium

enhancement (LGE) permits visualisation of focal replacement myocardial fibrosis, while T1

mapping pre- and post-gadolinium contrast enables non-invasive measurement of the

myocardial extracellular volume (ECV) fraction, a quantitative marker of myocardial diffuse

interstitial fibrosis.

Recently, the CRESCENT randomised trial (Cardiosleep Research Program on Obstructive

Sleep Apnoea, Blood Pressure Control and Maladaptive Myocardial Remodeling—Non-

inferiority Trial) showed that MAD was non-inferior to CPAP for reducing 24-hour mean

arterial BP in patients with hypertension and moderate-to-severe OSA, after 6 months of

treatment [13]. The present study was a cardiac MRI substudy of the CRESCENT trial and was

designed to determine the effects of MAD and CPAP on myocardial structure and function,

including markers of myocardial fibrosis, in patients with moderate-to-severe OSA.

Methods

Study Population and Trial Design

The CRESCENT trial design has been described previously [13]. Briefly, this was a

randomized, controlled, non-inferiority trial conducted in Singapore (NCT04119999).

Participants were recruited from October 1, 2019, to December 5, 2022, through medical

record screening at three public hospitals in Singapore. Inclusion criteria consisted of adults

aged ≥40 years with known hypertension and at least one other factor for high cardiovascular

risk for screening polysomnography, including diabetes mellitus; stroke or transient

ischaemic attack; significant coronary artery disease; chronic kidney disease with an

estimated glomerular filtration rate of less than 60mL/min/1.73m^2 or age of 75 years or older

[13]. Exclusion criteria included known OSA on treatment; Cheyne-Stokes breathing or

predominantly central sleep apnoea; secondary hypertension; unsuitable anatomy for MAD;

life expectancy <1 year; hypertensive crisis, acute coronary syndromes, or acute heart failure

in the past 30 days.

Participants underwent polysomnography following recruitment, and completed the Epworth

Sleepiness Scale (ESS) questionnaire. OSA was diagnosed based on the apnoea-hypopnoea

index (AHI), quantified as the total number of apnoeas or hypopnoeas per hour of sleep.

Patients diagnosed with moderate-to-severe OSA (AHI ≥15 events per hour) were randomly

assigned to treatment by MAD or CPAP in a 1:1 ratio. The treatment duration was 12

months. Device adherence was determined in the MAD group by an embedded compliance

micro-recorder chip (DentiTrac, Braebon), and in the CPAP group by a cloud-based

telemedicine management platform (Airview, ResMed Corp). Device adherence was defined

as ≥4 hours usage per night, beyond which CPAP treatment may reduce the incidence of

cardiovascular events [15]. The Institutional Review Board approved the trial (The Domain

Specific Review Board-C: 2019/00359, approved on August 28, 2019). All participants

provided written informed consent.

Cardiovascular magnetic resonance image acquisition

All patients in the CRESCENT cohort were invited and assessed for suitability for CMR.

Those who agreed and were eligible underwent a standardised CMR protocol with a Siemens

Aera 1.5 Tesla MRI scanner (Siemens Healthineers, Erlangen, Germany) at baseline and

following 12 months of treatment with MAD or CPAP. Balanced steady-state free-precession

cines were acquired in the standard long-axis views and a short-axis stack was acquired from

base to apex. LGE images were acquired at 10 min after 0.1 mmol/kg of gadobutrol

(Gadovist®, Bayer Pharma AG, Germany) with a phase-sensitive inversion-recovery

gradient-echo imaging sequence. The inversion time for optimal myocardial nulling was

selected from an inversion time scout sequence. T1 maps were acquired at the basal and mid-

ventricular short-axis levels, pre- and 15-min post-contrast with modified Look-Locker

inversion-recovery (MOLLI) 5s(3s)3s and 4s(1s)3s(1s)2s acquisition schemes, respectively.

CMR analysis

Image analysis was performed using CVI42 software (Circle Cardiovascular Imaging,

Calgary, Canada) by trained imaging fellows at the National Heart Research Institute of

Singapore CMR Core Laboratory, who were blinded to the patients' clinical status.

Ventricular volumes, mass and ejection fraction, were measured from the short-axis cine

stack, using manual contouring of the left ventricle in end-diastole and end-systole, excluding

papillary muscles, as detailed previously [16]. LV volumes and mass were indexed to body

surface area. The presence of LGE was assessed qualitatively by two readers according to the

recommendations by the Society of CMR [17]. Average native and post-contrast myocardial

T1 values were measured by placing a region of interest (ROI) within the middle third of the

short-axis myocardial wall at the basal- and mid-ventricular levels while avoiding areas of

focal LGE. The myocardium-blood pool interface was carefully avoided to prevent partial

volume effects. Pre- and post-contrast blood T1 values were measured in a ROI drawn within

the blood pool. The ECV fraction was calculated from the pre-and post-contrast average

blood and myocardial T1 values, as described previously [23, 24], and is reported as a mean

value from the basal and mid-ventricular slices. The myocardial interstitial volume was

calculated as: $\frac{ECV}{100} \times Myocardial\ volume$, where myocardial volume (mL) was defined as

myocardial mass (g)/1.05 g/mL. Myocyte volume was calculated as: $\left(1 - \frac{ECV}{100}\right) \times$

$Myocardial\ volume$. Myocardial strain was analysed in the cine images using the Tissue

Tracking Plugin (Circle Cardiovascular Imaging, Calgary, Canada).

Statistics

Normality for continuous variables was assessed using the Shapiro-Wilk test. Normally

distributed data are presented as mean ± standard deviation. Non-normally distributed data

are presented as median [interquartile range]. Comparisons were performed for continuous

variables before and after treatment using the parametric paired Student *t*-test or the non-

parametric Wilcoxon signed-ranked test. Pearson's correlation coefficient was used to assess

correlations between continuous variables. Categorical variables are presented as number

(percentage) and compared using the χ^2 test. Statistical analyses were performed using SPSS

Version 29 (Statistical Package for the Social Sciences, International Business Machines,

Inc., Armonk, New York, USA) and GraphPad Prism 9.4.1 (GraphPad Software, Inc., San

Diego, California, USA). A two-sided p-value <0.05 was considered as statistically

significant.

Results

Of the 220 participants in the CRESCENT study who were randomly allocated to either MAD

or CPAP in a 1:1 allocation, 101 patients underwent baseline CMR (Figure 1). Out of this

group, 84.2% (85 of 101) underwent serial CMR at 12 months and were included in this sub-study (median age: 61 years; 91% [77 of 85] males; MAD: 36; CPAP: 49).

At baseline, the median BMI was 28 [26-31] kg/m^2. The baseline 24-hour mean arterial BP was 96±8 mmHg. Of the cardiovascular co-morbidities, 61% (52 of 85) had coronary artery disease, and 60% (51 of 85) had diabetes mellitus. All patients had hypertension, and this diagnosis had been present in 52% (44 of 85) for over 5 years. OSA was classified as severe in 68% (58 of 85) of patients. The baseline median AHI for the cohort was 41 [27-59] events per hour. The ESS at baseline was 7.8 ± 4.3. The baseline CMR characteristics are given in Table 1. Patients in the MAD group were older compared to the CPAP group (MAD: 64 [57-69] years vs CPAP: 59 [53-64] years; p = 0.043). Otherwise, there were no clinical, sleep or CMR differences in baseline characteristics between the MAD and CPAP groups (Supplemental Table 1).

Valid adherence data at 12 months was available for 58% (21 of 36) in the MAD group. The mean duration of device usage per night was 4.6±2.4 hours in this group. In the MAD group, 62% (13 of 21) used the device for ≥4 hours per night and were classified as adherent. Adherence data was available for 92% (45 of 49) in the CPAP group. The mean duration of device usage per night in this group was 4.3±2.0 hours, with 64% (29 of 45) being adherent. The difference between groups in adherence was not statistically significant (p=0.57).

In the MAD group, the ECV fraction decreased from 24.9±2.3% at baseline to 24.0±2.2% at month 12; p=0.042). The ECV fraction decreased in the CPAP group from 25.1±1.9% at baseline to 24.5±1.8% at month 12 (p=0.016). Change in ECV fraction did not differ according to treatment device (MAD: -0.6[-1.6-0.4] % vs CPAP: -0.6[-2.1-0.5] %; p=0.94). Amongst the

CMR markers in the entire cohort, there was a reduction in the ECV fraction (baseline:

25.0±2.0 vs month 12: 24.3±2.0%; p=0.002), with associated reduction in the interstitial

volume (24.0[21.3-27.7] vs 23.3[20.4-27.4] mL; p=0.044) (Figure 2). All other CMR

parameters in the entire cohort, including LV mass and LV myocyte volume, did not differ, and

these results were consistent across treatment groups (Table 2).

An exploratory analysis of clinical and CMR markers associated with ECV fraction change

showed a reduction in the ECV fraction in obese patients (baseline BMI $\geq$30kg/m^2; baseline

ECV: 25.2[23.9-26.6]% vs month 12 ECV: 23.9[22.5-25.3]%; n=25; p<0.001). Furthermore,

obese patients were more likely to experience a reduction in the ECV fraction (change in obese:

-1.2[-1.9 to -0.3]% vs change in non-obese: -0.4[-1.6 to 0.8]%; p=0.026) (Figure 3;

Supplemental Table 2). Obese patients were more likely to experience an increase in the

myocyte volume (change in obese: 2.1[-0.6 to 6.4]mL vs change in non-obese: -0.6[-3.0 to

2.0]mL; p=0.025). However, myocyte volume did not increase significantly in the obese group

(baseline myocyte volume: 85[70-98]mL vs month 12 myocyte volume: 88[73-97]mL; n=25;

p=0.054). Obese patients had a higher AHI at baseline (54[42-69] events per hour vs 32[23-48]

events per hour; p<0.001), and experienced a greater reduction in AHI with treatment (58[42-

66] events per hour vs 31[23-46] events per hour; p=0.001).

Otherwise, there were no associations detected between ECV fraction change and change in

clinical, sleep or other CMR markers (Supplemental Table 3). Both adherence to treatment at

12 months and residual (month 12) AHI did not correlate with a change in the ECV fraction.

Discussion

To our knowledge, this is the first CMR study to assess the comparative effects of MAD and CPAP therapy for OSA on longitudinal change in cardiac functional parameters. The main finding in this study was that treatment of OSA, with either MAD or CPAP, was associated with a reduction in the ECV fraction, a surrogate marker of diffuse myocardial fibrosis, with associated decrease in the myocardial interstitial volume. Conversely, no change was observed in other CMR markers, including LV mass and myocyte volume.

OSA is thought to mediate myocardial fibrosis via several mechanisms. Chronic intermittent hypoxia, a hallmark of OSA, has been shown to induce cardiac inflammation, apoptosis and fibrosis in rats [18]. Heightened sympathetic drive due to recurrent apnoeas during sleep has been implicated in the development of cardiac interstitial fibrosis in animal models [19, 20]. Resting awake OSA patients have increased BP variability, which has been shown to induce myocardial fibrosis in hypertensive rats [20-22]. Alternating cycles of hypoxaemia and reoxygenation may trigger oxidative stress mechanisms, which are known to be involved in the development of myocardial fibrosis [20, 23]. Finally, OSA and hypertension share a strong epidemiological connection, with an estimated 50% of patients with hypertension having concomitant OSA [24]. There is extensive evidence linking the severity of OSA to the degree of BP elevation [25, 26]. Several mechanisms are implicated, including chronic intermittent hypoxia, large intrathoracic pressure swings, sympathetic nerve and renin-angiotensin aldosterone system activation, systemic inflammation, endothelial dysfunction and oxidative

stress [26, 27]. In turn, hypertension is known to cause both replacement and diffuse myocardial fibrosis [28, 29].

Treatment of OSA is known to target a number of pathways that have been linked to the development of myocardial fibrosis. The evidence is strongest for CPAP. In particular, CPAP has been shown to reduce sympathetic drive and acutely decrease BP during sleep [30, 31]. The chronic effects of CPAP on BP are more modest, with greater benefit evident in hypertensive rather than normotensive patients [32]. CPAP reduces nocturnal, in addition to waking, BP variability [33, 34]. Markers of oxidative stress are reduced with CPAP therapy [35, 36]. CPAP has also been shown to improve nocturnal hypoxemia [37]. Therefore, it is plausible that CPAP may reduce myocardial fibrosis in OSA through these mechanisms.

Myocardial fibrosis includes both replacement fibrosis and reactive interstitial fibrosis. Replacement fibrosis, represented by late gadolinium enhancement in CMR imaging, corresponds to the replacement of myocytes with collagen following myocyte necrosis and is thought to be irreversible [38]. Reactive interstitial fibrosis, measured with T1 mapping and ECV fraction at CMR, is characterised by collagen deposition by myofibroblasts within the interstitium and perivascular space. It is considered a marker of intermediate disease severity and potentially reversible [39, 40]. The observed reduction in the ECV fraction, along with a reduction in the absolute myocardial interstitial volume, therefore indicates that treatment of OSA with MAD or CPAP may specifically reduce the burden of myocardial fibrosis through effects on the interstitium. Myocardial fibrosis regression has been documented previously following interventions in other cardiac diseases, including aortic valve replacement for aortic

stenosis and pirfenidone, an oral antifibrotic agent, for heart failure with preserved ejection

fraction [40, 41]. Both studies observed changes in ECV fraction and interstitial volume after

one year of treatment. The magnitude of ECV fraction reduction was higher with pirfenidone (-

1.21% compared to placebo) compared to this study. This likely reflects the more advanced

heart failure population in that study, with baseline mean myocardial ECV fraction measuring

30.1%. ECV fraction was paradoxically increased following AVR for aortic stenosis due to

greater effects on the myocyte compartment.

The reduction in ECV fraction was noted across both MAD and CPAP groups. A growing body

of evidence suggests that MAD may have similar cardiovascular benefits to CPAP. MAD has

been shown to improve nocturnal hypoxaemia [42]. MAD has a similar BP-lowering effect

compared to CPAP [13]. There is emerging evidence to suggest that MAD treatment can

improve cardiac autonomic function [43]. Based on these benefits, it is plausible that MAD

therapy would also be able to reduce myocardial fibrosis, as observed in this study. This is an

important finding, since MADs are preferred by patients with OSA compared to CPAP, and

treatment adherence appears to be higher with MAD therapy [44-46], indicating great potential

to improve cardiovascular health.

In this study, there was no difference observed in left ventricular mass, atrial and ventricular

volumes, and ventricular function following treatment for OSA. Prior to this study, a few

longitudinal CMR studies have assessed for change in cardiac functional parameters following

initiation of CPAP in OSA. Results have been mixed. One study showed reduction in indexed

right and left atrial volumes, indexed RV end diastolic volume, and indexed left ventricular

mass at 1 year following initiation of CPAP therapy [8]. Notably, the cohort in that study at baseline was generally heavier (mean BMI 38 kg/m^2), more symptomatic (mean ESS 14) and had more severe OSA (mean AHI 63 events/hour), which may have explained the discrepancy in findings compared to our study. Two studies have shown improvement in RV volumes or RV ejection fraction with CPAP therapy [9, 47]. In both studies, patients had a higher BMI at baseline (33-35 kg/m^2) compared to our study (28 kg/m^2). Another study showed no change in CMR parameters after four months of CPAP therapy in non-obese and obese CPAP-naïve patients [48]. The patients included were most similar to our cohort based on baseline symptoms (mean ESS 9.5), BMI (31.6 kg/m^2) and severity of OSA (mean AHI 36 events/hour), which may have explained the similarity in findings. Interestingly, the authors of that study found that the presence of obesity modified the effect of CPAP on indexed left atrial volume. In our study, we noted that obese patients (defined according to the WHO definition of BMI ≥30kg/m^2) experienced a reduction in ECV fraction, whereas non-obese patients did not. Obesity may worsen OSA due to increased fat deposition in the tissues surrounding the upper airway, predisposing to apnoea [49]. Indeed, the obese group in this study had more severe OSA at baseline, recording a higher baseline AHI. Furthermore, the obese group experienced a greater reduction in AHI following 12 months of OSA treatment. This may have explained why OSA treatment was associated with a reduction in ECV fraction in the obese but not in the non-obese group.

The finding of a change in myocardial fibrosis markers without associated changes in cardiac mass, volumes or function has precedent. Recently, pirfenidone was found to reduce the ECV fraction in patients with heart failure without any effects on cardiac functional parameters or LV mass [40]. This is an antifibrotic agent without haemodynamic effect and is therefore

thought to target the extracellular matrix. In an earlier study, lisinopril caused regression of myocardial fibrosis in patients with hypertensive heart disease, as measured with the LV collagen fraction and myocardial hydroxyproline concentration from endomyocardial biopsy, without any effects on LV hypertrophy [50]. These results were in keeping with the perception that haemodynamics are the most relevant determinants of LVH. Since the BP was controlled at baseline, no changes in LVH were detected [50]. Similarly, the patients in our study had well-controlled BP at baseline, which may have explained why no regression in LV mass was observed.

Limitations

Our study has a few limitations. First, this was an exploratory analysis in a CMR substudy of the CRESCENT trial. The hypothesis that OSA treatment would reduce the myocardial ECV fraction was not *a priori*. Second, this was a single-centre CMR study. Although the sample size was small, this was similar to previous CMR studies assessing the longitudinal effect of OSA treatment on cardiac functional parameters. Third, the participants were all of Chinese ethnicity, which may limit the generalisability [13].

Conclusion

Treatment of moderate-to-severe OSA, with either MAD or CPAP, in patients with hypertension and high cardiovascular risk, is associated with a reduction in myocardial ECV fraction, a surrogate marker of diffuse myocardial fibrosis, at 12 months, with an associated

1 reduction in the myocardial interstitial volume. This study provides further support for the

2 use of MAD as a viable alternative to CPAP in reducing cardiovascular risk in patients with

3 OSA.

Sources of Funding

7 This study was supported by a Clinician Scientist Award from the National Medical Research

8 Council of Singapore (Grant number: CSASI18may-0001) and the USyd-NUS Partnership

9 Collaboration Award, a joint award from the National University of Singapore and the

10 University of Sydney.

Availability of data and materials

14 The datasets generated and analysed for the current study are not publicly available. Please

15 contact the corresponding author for data requests.

Disclosures

Dr Cistulli has an appointment as an endowed Academic Chair at the University of Sydney

that was created from ResMed funding (he receives no personal fees, and this relationship is

managed by an Oversight Committee of the University); has received research support from

ResMed, SomnoMed, Zephyr Sleep Technologies, and Bayer; is a consultant/adviser to

Signifier Medical Technologies, SomnoMed, ResMed, and Sunrise Medical; and has a

pecuniary interest in SomnoMed related to a previous role in R&D (2004). Dr Ugander is

principal investigator for an institutional research and development agreement regarding

cardiovascular magnetic resonance imaging between Karolinska University Hospital and

Siemens. Dr Lee has received an honorarium from ResMed (2022); and has received a

research grant from Boston Scientific Corporation. All other authors have reported that they

have no relationships relevant to the contents of this paper to disclose.

References

1.   Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019;7(8):687-98. Epub 2019/07/14. doi: 10.1016/S2213-2600(19)30198-5. PubMed PMID: 31300334; PubMed Central PMCID: PMCPMC7007763.

2.   Levy P, Kohler M, McNicholas WT, Barbe F, McEvoy RD, Somers VK, et al. Obstructive sleep apnoea syndrome. Nat Rev Dis Primers. 2015;1:15015. Epub 2015/01/01. doi: 10.1038/nrdp.2015.15. PubMed PMID: 27188535.

3.   Eckert DJ, Malhotra A. Pathophysiology of adult obstructive sleep apnea. Proc Am Thorac Soc. 2008;5(2):144-53. Epub 2008/02/06. doi: 10.1513/pats.200707-114MG. PubMed PMID: 18250206; PubMed Central PMCID: PMCPMC2628457.

4.   Baguet JP, Barone-Rochette G, Tamisier R, Levy P, Pepin JL. Mechanisms of cardiac dysfunction in obstructive sleep apnea. Nat Rev Cardiol. 2012;9(12):679-88. Epub 2012/09/26. doi: 10.1038/nrcardio.2012.141. PubMed PMID: 23007221.

5.   Cloward TV, Walker JM, Farney RJ, Anderson JL. Left ventricular hypertrophy is a common echocardiographic abnormality in severe obstructive sleep apnea and reverses with nasal continuous positive airway pressure. Chest. 2003;124(2):594-601. Epub 2003/08/09. doi: 10.1378/chest.124.2.594. PubMed PMID: 12907548.

6.   Laaban JP, Pascal-Sebaoun S, Bloch E, Orvoen-Frija E, Oppert JM, Huchon G. Left ventricular systolic dysfunction in patients with obstructive sleep apnea syndrome. Chest. 2002;122(4):1133-8. Epub 2002/10/16. doi: 10.1378/chest.122.4.1133. PubMed PMID: 12377833.

7.   Shah NA, Reid M, Kizer JR, Sharma RK, Shah RV, Kundel V, et al. Sleep-disordered breathing and left ventricular scar on cardiac magnetic resonance: results of the Multi-Ethnic Study of Atherosclerosis. J Clin Sleep Med. 2020;16(6):855-62. Epub 2020/02/08. doi: 10.5664/jcsm.8340. PubMed PMID: 32029066; PubMed Central PMCID: PMCPMC7849673.

8.   Colish J, Walker JR, Elmayergi N, Almutairi S, Alharbi F, Lytwyn M, et al. Obstructive sleep apnea: effects of continuous positive airway pressure on cardiac remodeling as assessed by cardiac biomarkers, echocardiography, and cardiac MRI. Chest. 2012;141(3):674-81. Epub 2011/08/13. doi: 10.1378/chest.11-0615. PubMed PMID: 21835901.

9.   Wuest W, May MS, Wiesmueller M, Uder M, Schmid A. Effect of long term CPAP therapy on cardiac parameters assessed with cardiac MRI. Int J Cardiovasc Imaging. 2021;37(2):613-21. Epub 2020/09/15. doi: 10.1007/s10554-020-02024-y. PubMed PMID: 32926309; PubMed Central PMCID: PMCPMC8423704.

10.   Sun H, Shi J, Li M, Chen X. Impact of continuous positive airway pressure treatment on left ventricular ejection fraction in patients with obstructive sleep apnea: a meta-analysis of randomized controlled trials. PLoS One. 2013;8(5):e62298. Epub 2013/05/08. doi: 10.1371/journal.pone.0062298. PubMed PMID: 23650511; PubMed Central PMCID: PMCPMC3641077.

11.   Almeida FR, Henrich N, Marra C, Lynd LD, Lowe AA, Tsuda H, et al. Patient preferences and experiences of CPAP and oral appliances for the treatment of obstructive sleep apnea: a qualitative analysis. Sleep Breath. 2013;17(2):659-66. Epub 2012/07/27. doi: 10.1007/s11325-012-0739-6. PubMed PMID: 22833346.

12.   Trzepizur W, Cistulli PA, Glos M, Vielle B, Sutherland K, Wijkstra PJ, et al. Health
outcomes of continuous positive airway pressure versus mandibular advancement device
for the treatment of severe obstructive sleep apnea: an individual participant data meta-
analysis. Sleep. 2021;44(7). Epub 2021/01/26. doi: 10.1093/sleep/zsab015. PubMed PMID:
33493338.
13.   Ou YH, Colpani JT, Cheong CS, Loke W, Thant AT, Shih EC, et al. Mandibular
Advancement vs CPAP for Blood Pressure Reduction in Patients With Obstructive Sleep
Apnea. J Am Coll Cardiol. 2024;83(18):1760-72. Epub 2024/04/09. doi:
10.1016/j.jacc.2024.03.359. PubMed PMID: 38588926.
14.   Dieltjens M, Vanderveken OM, Shivalkar B, Van Haesendonck G, Kastoer C,
Heidbuchel H, et al. Mandibular advancement device treatment and reverse left ventricular
hypertrophic remodeling in patients with obstructive sleep apnea. J Clin Sleep Med.
2022;18(3):903-9. Epub 2021/11/04. doi: 10.5664/jcsm.9766. PubMed PMID: 34728052;
PubMed Central PMCID: PMCPMC8883081.
15.   Barbe F, Duran-Cantolla J, Sanchez-de-la-Torre M, Martinez-Alonso M, Carmona C,
Barcelo A, et al. Effect of continuous positive airway pressure on the incidence of
hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea:
a randomized controlled trial. JAMA. 2012;307(20):2161-8. Epub 2012/05/24. doi:
10.1001/jama.2012.4366. PubMed PMID: 22618923.
16.   Le TT, Tan RS, De Deyn M, Goh EP, Han Y, Leong BR, et al. Cardiovascular magnetic
resonance reference ranges for the heart and aorta in Chinese at 3T. J Cardiovasc Magn
Reson. 2016;18:21. Epub 2016/04/14. doi: 10.1186/s12968-016-0236-3. PubMed PMID:
27071974; PubMed Central PMCID: PMCPMC4830061.
17.   Schulz-Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA, Friedrich MG, et al.
Standardized image interpretation and post processing in cardiovascular magnetic
resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task
force on standardized post processing. J Cardiovasc Magn Reson. 2013;15(1):35. Epub
2013/05/03. doi: 10.1186/1532-429X-15-35. PubMed PMID: 23634753; PubMed Central
PMCID: PMCPMC3695769.
18.   Wei Q, Bian Y, Yu F, Zhang Q, Zhang G, Li Y, et al. Chronic intermittent hypoxia
induces cardiac inflammation and dysfunction in a rat obstructive sleep apnea model. J
Biomed Res. 2016;30(6):490-5. Epub 2016/12/08. doi: 10.7555/JBR.30.20160110. PubMed
PMID: 27924067; PubMed Central PMCID: PMCPMC5138581.
19.   Perlini S, Palladini G, Ferrero I, Tozzi R, Fallarini S, Facoetti A, et al. Sympathectomy
or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload
hypertrophy. Hypertension. 2005;46(5):1213-8. Epub 2005/10/12. doi:
10.1161/01.HYP.0000185689.65045.4c. PubMed PMID: 16216989.
20.   Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, et al. Sleep apnea
and cardiovascular disease: an American Heart Association/american College Of Cardiology
Foundation Scientific Statement from the American Heart Association Council for High Blood
Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke
Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart,
Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes
of Health). Circulation. 2008;118(10):1080-111. Epub 2008/08/30. doi:
10.1161/CIRCULATIONAHA.107.189375. PubMed PMID: 18725495.

21.   Narkiewicz K, Montano N, Cogliati C, van de Borne PJ, Dyken ME, Somers VK. Altered
cardiovascular variability in obstructive sleep apnea. Circulation. 1998;98(11):1071-7. Epub
1998/09/16. doi: 10.1161/01.cir.98.11.1071. PubMed PMID: 9736593.
22.   Yasuoka S, Kai H, Kajimoto H, Kudo H, Takayama N, Anegawa T, et al. Blood pressure
variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in
hypertensive rats. Circ J. 2013;77(6):1474-81. Epub 2013/03/09. doi: 10.1253/circj.cj-12-
1253. PubMed PMID: 23470864.
23.   Dhalla NS, Elimban V, Bartekova M, Adameova A. Involvement of Oxidative Stress in
the Development of Subcellular Defects and Heart Disease. Biomedicines. 2022;10(2). Epub
2022/02/26. doi: 10.3390/biomedicines10020393. PubMed PMID: 35203602; PubMed
Central PMCID: PMCPMC8962363.
24.   Konecny T, Kara T, Somers VK. Obstructive sleep apnea and hypertension: an update.
Hypertension. 2014;63(2):203-9. Epub 2014/01/01. doi:
10.1161/HYPERTENSIONAHA.113.00613. PubMed PMID: 24379177; PubMed Central
PMCID: PMCPMC4249687.
25.   Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, et al. Association of
sleep-disordered breathing, sleep apnea, and hypertension in a large community-based
study. Sleep Heart Health Study. JAMA. 2000;283(14):1829-36. Epub 2000/04/19. doi:
10.1001/jama.283.14.1829. PubMed PMID: 10770144.
26.   Cai A, Wang L, Zhou Y. Hypertension and obstructive sleep apnea. Hypertens Res.
2016;39(6):391-5. Epub 2016/02/19. doi: 10.1038/hr.2016.11. PubMed PMID: 26888120.
27.   Hoshide S, Kario K, Chia YC, Siddique S, Buranakitjaroen P, Tsoi K, et al.
Characteristics of hypertension in obstructive sleep apnea: An Asian experience. J Clin
Hypertens (Greenwich). 2021;23(3):489-95. Epub 2021/03/12. doi: 10.1111/jch.14184.
PubMed PMID: 33705599; PubMed Central PMCID: PMCPMC8029541.
28.   Gonzalez A, Lopez B, Ravassa S, San Jose G, Latasa I, Butler J, et al. Myocardial
Interstitial Fibrosis in Hypertensive Heart Disease: From Mechanisms to Clinical
Management. Hypertension. 2024;81(2):218-28. Epub 2023/12/12. doi:
10.1161/HYPERTENSIONAHA.123.21708. PubMed PMID: 38084597.
29.   Diez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens (Greenwich).
2007;9(7):546-50. Epub 2007/07/10. doi: 10.1111/j.1524-6175.2007.06626.x. PubMed
PMID: 17617765; PubMed Central PMCID: PMCPMC8110048.
30.   Hedner J, Darpo B, Ejnell H, Carlson J, Caidahl K. Reduction in sympathetic activity
after long-term CPAP treatment in sleep apnoea: cardiovascular implications. Eur Respir J.
1995;8(2):222-9. Epub 1995/02/01. doi: 10.1183/09031936.95.08020222. PubMed PMID:
7758555.
31.   Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in
obstructive sleep apnea. J Clin Invest. 1995;96(4):1897-904. Epub 1995/10/01. doi:
10.1172/JCI118235. PubMed PMID: 7560081; PubMed Central PMCID: PMCPMC185826.
32.   Engleman HM, Asgari-Jirhandeh N, McLeod AL, Ramsay CF, Deary IJ, Douglas NJ. Self-
reported use of CPAP and benefits of CPAP therapy: a patient survey. Chest.
1996;109(6):1470-6. Epub 1996/06/01. doi: 10.1378/chest.109.6.1470. PubMed PMID:
8769496.
33.   Marrone O, Bonsignore MR. Blood-pressure variability in patients with obstructive
sleep apnea: current perspectives. Nat Sci Sleep. 2018;10:229-42. Epub 2018/09/04. doi:
10.2147/NSS.S148543. PubMed PMID: 30174467; PubMed Central PMCID:
PMCPMC6109653.

34.   Ali NJ, Davies RJ, Fleetham JA, Stradling JR. The acute effects of continuous positive
airway pressure and oxygen administration on blood pressure during obstructive sleep
apnea. Chest. 1992;101(6):1526-32. Epub 1992/06/01. doi: 10.1378/chest.101.6.1526.
PubMed PMID: 1600769.
35.   Eisele HJ, Markart P, Schulz R. Obstructive Sleep Apnea, Oxidative Stress, and
Cardiovascular Disease: Evidence from Human Studies. Oxid Med Cell Longev.
2015;2015:608438. Epub 2015/07/15. doi: 10.1155/2015/608438. PubMed PMID:
26167241; PubMed Central PMCID: PMCPMC4475750.
36.   Stanek A, Brozyna-Tkaczyk K, Myslinski W. Oxidative Stress Markers among
Obstructive Sleep Apnea Patients. Oxid Med Cell Longev. 2021;2021:9681595. Epub
2021/08/03. doi: 10.1155/2021/9681595. PubMed PMID: 34336121; PubMed Central
PMCID: PMCPMC8321764.
37.   Giles TL, Lasserson TJ, Smith B, White J, Wright JJ, Cates CJ. Continuous positive
airways pressure for obstructive sleep apnoea in adults. Cochrane Database of Systematic
Reviews. 2006;(3). doi: 10.1002/14651858.CD001106.pub3. PubMed PMID: CD001106.
38.   Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA. Assessment of myocardial fibrosis
with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57(8):891-903. Epub
2011/02/19. doi: 10.1016/j.jacc.2010.11.013. PubMed PMID: 21329834; PubMed Central
PMCID: PMCPMC3081658.
39.   Lewis GA, Dodd S, Naish JH, Selvanayagam JB, Dweck MR, Miller CA. Considerations
for Clinical Trials Targeting the Myocardial Interstitium. JACC Cardiovasc Imaging.
2019;12(11 Pt 2):2319-31. Epub 2019/08/20. doi: 10.1016/j.jcmg.2019.03.034. PubMed
PMID: 31422145.
40.   Lewis GA, Dodd S, Clayton D, Bedson E, Eccleson H, Schelbert EB, et al. Pirfenidone in
heart failure with preserved ejection fraction: a randomized phase 2 trial. Nat Med.
2021;27(8):1477-82. Epub 2021/08/14. doi: 10.1038/s41591-021-01452-0. PubMed PMID:
34385704.
41.   Treibel TA, Kozor R, Schofield R, Benedetti G, Fontana M, Bhuva AN, et al. Reverse
Myocardial Remodeling Following Valve Replacement in Patients With Aortic Stenosis. J Am
Coll Cardiol. 2018;71(8):860-71. Epub 2018/02/24. doi: 10.1016/j.jacc.2017.12.035. PubMed
PMID: 29471937; PubMed Central PMCID: PMCPMC5821681.
42.   Park P, Jeon HW, Han DH, Won TB, Kim DY, Rhee CS, et al. Therapeutic outcomes of
mandibular advancement devices as an initial treatment modality for obstructive sleep
apnea. Medicine (Baltimore). 2016;95(46):e5265. Epub 2016/11/20. doi:
10.1097/MD.0000000000005265. PubMed PMID: 27861349; PubMed Central PMCID:
PMCPMC5120906 indicated no financial conflicts of interest.
43.   Ucak S, Dissanayake HU, Sutherland K, Bin YS, de Chazal P, Cistulli PA. Effect of
mandibular advancement splint therapy on cardiac autonomic function in obstructive sleep
apnoea. Sleep Breath. 2024;28(1):349-57. Epub 2023/09/29. doi: 10.1007/s11325-023-
02924-y. PubMed PMID: 37770793; PubMed Central PMCID: PMCPMC10955011.
44.   Tan YK, L'Estrange PR, Luo YM, Smith C, Grant HR, Simonds AK, et al. Mandibular
advancement splints and continuous positive airway pressure in patients with obstructive
sleep apnoea: a randomized cross-over trial. Eur J Orthod. 2002;24(3):239-49. Epub
2002/07/30. doi: 10.1093/ejo/24.3.239. PubMed PMID: 12143088.
45.   White DP, Shafazand S. Mandibular advancement device vs. CPAP in the treatment
of obstructive sleep apnea: are they equally effective in Short term health outcomes? J Clin

Sleep Med. 2013;9(9):971-2. Epub 2013/09/03. doi: 10.5664/jcsm.3008. PubMed PMID:
23997711; PubMed Central PMCID: PMCPMC3746726.
46.   Gagnadoux F, Fleury B, Vielle B, Petelle B, Meslier N, N'Guyen XL, et al. Titrated
mandibular advancement versus positive airway pressure for sleep apnoea. Eur Respir J.
2009;34(4):914-20. Epub 2009/03/28. doi: 10.1183/09031936.00148208. PubMed PMID:
19324954.
47.   Magalang UJ, Richards K, McCarthy B, Fathala A, Khan M, Parinandi N, et al.
Continuous positive airway pressure therapy reduces right ventricular volume in patients
with obstructive sleep apnea: a cardiovascular magnetic resonance study. J Clin Sleep Med.
2009;5(2):110-4. Epub 2009/12/09. PubMed PMID: 19968042; PubMed Central PMCID:
PMCPMC2670328.
48.   Xu L, Keenan BT, Maislin D, Gislason T, Benediktsdottir B, Gudmundsdottir S, et al.
Effect of Obstructive Sleep Apnea and Positive Airway Pressure Therapy on Cardiac
Remodeling as Assessed by Cardiac Biomarker and Magnetic Resonance Imaging in
Nonobese and Obese Adults. Hypertension. 2021;77(3):980-92. Epub 2021/01/20. doi:
10.1161/HYPERTENSIONAHA.120.15882. PubMed PMID: 33461313; PubMed Central
PMCID: PMCPMC7878363.
49.   Romero-Corral A, Caples SM, Lopez-Jimenez F, Somers VK. Interactions between
obesity and obstructive sleep apnea: implications for treatment. Chest. 2010;137(3):711-9.
Epub 2010/03/06. doi: 10.1378/chest.09-0360. PubMed PMID: 20202954; PubMed Central
PMCID: PMCPMC3021364.
50.   Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in
patients with hypertensive heart disease. Circulation. 2000;102(12):1388-93. Epub
2000/09/20. doi: 10.1161/01.cir.102.12.1388. PubMed PMID: 10993857.
25
26
27

Figure Titles and Legends

Figure 1. Flow chart of patient inclusion. Abbreviations: OSA: Obstructive sleep apnoea;

PSG: polysomnography; MAD: Mandibular advancement device; CPAP: Continuous

positive airways pressure; CMR: Cardiovascular magnetic resonance.

Figure 2. Extracellular volume fraction (ECV) fraction before and after OSA treatment.

ECV fraction (panel A) and absolute myocardial interstitial volume (panel C) were reduced

following 12 months of treatment for OSA. Left ventricular mass (panel B) and myocyte

volume (panel D) did not change following treatment. Whiskers were plotted using the Tukey

method.

Figure 3. Forest plot for subgroup analyses of treatment effect. Patients with obesity

(BMI $\geq$30kg/m^2) were more likely to experience a reduction in ECV fraction with OSA

treatment. Median and interquartile range are shown for all subgroup analyses. Dotted line

shows no effect point. Abbreviations: BMI: Body mass index; SBP: Systolic blood pressure;

AHI: Apnoea-hypopnoea index; ACEi: Angiotensin-converting enzyme inhibitor; ARB:

Angiotensin II receptor blocker.

Table 1. Clinical, sleep and CMR characteristics of the cohort at baseline and following 12 months of OSA treatment

	Baseline (n=85)	Follow-up (n=85)	p Value
Clinical			
Age, years	61 [54-66]		
Male sex, n (%)	77 (91)		
24-hour, mmHg			
Mean BP	96 ± 8		
Systolic BP	126 ± 11		
Diastolic BP	80 ± 8		
Body mass index, kg/m^2	27.8 [25.6-30.5]	28.8 [25.5-30.7]	0.04
Body surface area, m^2	1.92 [1.78-2.03]	1.91 [1.78-2.03]	0.80
Co-morbidities, n (%)			
Coronary artery disease	52 (61)		
Diabetes Mellitus	51 (60)		
Smoker	3 (4)		
Hypertension duration, y			
<5, n (%)	18 (21)		
5 – 10, n (%)	14 (17)		
>10, n (%)	30 (35)		
Unknown, n (%)	23 (27)		
Medications, n (%)			
Beta Blocker	47 (55)		
ACEi or ARB	72 (85)		
CCB	33 (39)		
Diuretic	12 (14)		
Statin	73 (86)		
Sleep			
AHI, events per hour	41 [27-59]	2 [1-4]*	<0.001
Patients with AHI			
<15 events per hour	0 (0)	45 (98)*	
15 to <30 events per hour	27 (32)	0 (0)*	
≥30 events per hour	58 (68)	1 (2)*	<0.001
Epworth sleepiness scale	7.8 ± 4.3		
CMR Markers			
LVEDV, mL	146 ± 39	148 ± 39	0.45
LVESV, mL	66 ± 31	67 ± 32	0.58

LVSV, mL	80 ± 18	81 ± 15	0.66
LV mass, g	102 [90-120]	103 [88-119]	0.72
LV ejection fraction, %	56 ± 9	56 ± 9	0.91
GLS, %	-15.0 ± 2.9	-15.5 ± 2.8	0.76
RVEDV, mL	145 ± 34	145 ± 30	0.72
RVESV, mL	64 ± 22	64 ± 20	0.98
RVSV, mL	80 ± 18	81 ± 15	0.58
RV ejection fraction, %	56 ± 8	56 ± 7	0.77
RA area, m^2	21 [18-24]	21 [18-23]	0.28
LA volume, mL	85 [68-101]	84 [71-101]	0.85
LGE Type			
Nil, n (%)	40 (47)		
Non-ischaemic, n (%)	12 (14)		
Ischaemic, n (%)	32 (38)		
Both, n (%)	1 (1)		
ECV fraction, %	25.0 ± 2.0	24.3 ± 2.0	0.002
Interstitial volume, mL	24.0 [21.3-27.7]	23.3 [20.4-27.4]	0.044
Myocyte volume, mL	72.9 [64.3-86.4]	73.4 [63.8-85.5]	0.52

Values are given as median [interquartile range], mean ± SD or number (percentage).

Abbreviations:; ACEi: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin II receptor blocker; CCB: Calcium channel blocker; AHI: Apnoea-hypopnoea index; LVEDV: Left ventricular end-diastolic volume; LVESV: Left ventricular end-systolic volume; LVSV: Left ventricular stroke volume; GLS: Global longitudinal strain; RVEDV: Right ventricular end-diastolic volume; RVESV: Right ventricular end-systolic volume; RVSV: Right ventricular stroke volume; RA: Right atrial; LA: Left atrial; LGE: Late gadolinium enhancement; ECV: Extracellular volume.

*Follow-up data only available for CPAP group

Table 2. Change in CMR characteristics of the cohort following 12 months of treatment for OSA according to treatment group.

	MAD (n=36)	CPAP (n=49)	p Value
Change in CMR Markers			
LVEDV, mL	0.5 [-11.8 to 8.3]	2.0 [-3.0 to 8.0]	0.31
LVESV, mL	3.0 [-8.0 to 8.8]	2.0 [-7.5 to 8.0]	0.98
LVSV, mL	-1.5 [-5.8 to 7.0]	2.0 [-5.0 to 9.0]	0.17
LV mass, g	-0.8 [-5.3-3.8]	-0.1 [-3.7-4.9]	0.47
LV ejection fraction, %	-0.8 ± 5.9	0.7 ± 7.1	0.32
GLS, %	0.2 ± 1.7	-0.1 ± 2.5	0.54
RVEDV, mL	0.0 [-8.0 to 7.0]	2.0 [-3.0 to 8.5]	0.24
RVESV, mL	0.3 ± 13.4	-0.2 ± 9.9	0.86
RVSV, mL	-2.0 ± 13.0	2.6 ± 9.0	0.06
RV ejection fraction, %	-0.9 ± 6.1	0.9 ± 5.5	0.18
RA area, m^2	0 [-2 to 1]	-1 [-2 to 1]	0.75
LA volume, mL	-1.7 [-14.9 to 12.5]	3.4 [-7.0 to 13.4]	0.41
ECV fraction, %	-0.6 [-1.6 to 0.4]	-0.6 [-2.1 to 0.5]	0.94
Interstitial volume, mL	-0.6 [-2.1 to 1.1]	-0.5 [-1.8 to 1.2]	0.57
Myocyte volume, mL	0.3 [-5.1 to 2.9]	0.7 [-2.2 to 3.8]	0.47

Values are given as median [interquartile range] or mean ± SD.

Abbreviations: LVEDV: Left ventricular end-diastolic volume; LVESV: Left ventricular end-systolic volume; LVSV: Left ventricular stroke volume; GLS: Global longitudinal strain; RVEDV: Right ventricular end-diastolic volume; RVESV: Right ventricular end-systolic volume; RVSV: Right ventricular stroke volume; RA: Right atrial; LA: Left atrial; ECV: Extracellular volume.